Skip to main content
Oxford University Press - PMC COVID-19 Collection logoLink to Oxford University Press - PMC COVID-19 Collection
. 2022 Jul 1:jiac281. doi: 10.1093/infdis/jiac281

Point Prevalence Estimates of Activity-Limiting Long-Term Symptoms among U.S. Adults ≥1 Month After Reported SARS-CoV-2 Infection, November 1, 2021

Mark W Tenforde 1,, Owen J Devine 2, Heather E Reese 3, Benjamin J Silk 4, A Danielle Iuliano 5, Ryan Threlkel 6, Quan M Vu 7, Ian D Plumb 8, Betsy L Cadwell 9, Charles Rose 10, Molly K Steele 11, Melissa Briggs-Hagen 12, Daniel Ayoubkhani 13, Piotr Pawelek 14, Vahé Nafilyan 15, Sharon H Saydah 16, Jeanne Bertolli 17
PMCID: PMC9278232  PMID: 35776165

Abstract

Background

Although most adults infected with SARS-CoV-2 fully recover, a proportion have ongoing symptoms, or post-COVID conditions (PCC), after infection. The objective of this analysis was to estimate the number of US adults with activity-limiting PCC on November 1, 2021.

Methods

We modeled the prevalence of PCC using reported infections occurring from February 1, 2020 – September 30, 2021, and population-based, household survey data on new activity-limiting symptoms ≥1 month following SARS-CoV-2 infection. From these data sources, we estimated the number and proportion of US adults with activity-limiting PCC on November 1, 2021, as 95% uncertainty intervals, stratified by sex and age. Sensitivity analyses adjusted for under-ascertainment of infections and uncertainty about symptom duration.

Results

On November 1, 2021, at least 3.0–5.0 million US adults were estimated to have activity-limiting PCC of ≥1 month duration, or 1.2%–1.9% of US adults. Population prevalence was higher in females (1.4%–2.2%) than males. The estimated prevalence after adjusting for under-ascertainment of infections was 1.7%–3.8%.

Conclusion

Millions of US adults were estimated to have activity-limiting PCC. These estimates can support future efforts to address the impact of PCC on the U.S. population.

Keywords: Post-COVID conditions, long COVID, disability, COVID-19, modeling, prevalence

Contributor Information

Mark W Tenforde, CDC COVID-19 Response Team, Atlanta, GA, USA.

Owen J Devine, Eagle Global Scientific, LLC, Alpharetta, GA, USA.

Heather E Reese, CDC COVID-19 Response Team, Atlanta, GA, USA.

Benjamin J Silk, CDC COVID-19 Response Team, Atlanta, GA, USA.

A Danielle Iuliano, CDC COVID-19 Response Team, Atlanta, GA, USA.

Ryan Threlkel, General Dynamics Information Technology, Inc., Atlanta, GA, USA.

Quan M Vu, CDC COVID-19 Response Team, Atlanta, GA, USA.

Ian D Plumb, CDC COVID-19 Response Team, Atlanta, GA, USA.

Betsy L Cadwell, CDC COVID-19 Response Team, Atlanta, GA, USA.

Charles Rose, CDC COVID-19 Response Team, Atlanta, GA, USA.

Molly K Steele, CDC COVID-19 Response Team, Atlanta, GA, USA.

Melissa Briggs-Hagen, CDC COVID-19 Response Team, Atlanta, GA, USA.

Daniel Ayoubkhani, Office for National Statistics, Newport, UK.

Piotr Pawelek, Office for National Statistics, Newport, UK.

Vahé Nafilyan, Office for National Statistics, Newport, UK.

Sharon H Saydah, CDC COVID-19 Response Team, Atlanta, GA, USA.

Jeanne Bertolli, CDC COVID-19 Response Team, Atlanta, GA, USA.

Supplementary Material

jiac281_Supplementary_Data

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

jiac281_Supplementary_Data

Articles from The Journal of Infectious Diseases are provided here courtesy of Oxford University Press

RESOURCES